- Conditions
- Cataracts, Meibomian Gland Dysfunction (MGD)
- Interventions
- LipiFlow Thermal Pulsation System
- Device
- Lead sponsor
- Johnson & Johnson Surgical Vision, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- Bakersfield, California • Chevy Chase, Maryland • Pennington, New Jersey + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Intraocular Lens Replacement
- Interventions
- OMS302, Placebo
- Drug
- Lead sponsor
- Omeros Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 13
- States / cities
- Chandler, Arizona • Los Angeles, California • Fort Myers, Florida + 10 more
- Conditions
- Cataract
- Interventions
- enVista MX60E, enVista MX60EF
- Device
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 501 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 23
- States / cities
- Fayetteville, Arkansas • Garden Grove, California • Northridge, California + 19 more
- Conditions
- Cataract
- Interventions
- OMS302 Solution, OMS302 Mydriatic Solution, OMS302 Anti-inflammatory Solution, Balanced Salt Solution (BSS) Solution
- Drug
- Lead sponsor
- Omeros Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 24
- States / cities
- Chandler, Arizona • Glendale, Arizona • Little Rock, Arkansas + 21 more
- Conditions
- Open Angle Glaucoma
- Interventions
- Transluminal viscoelastic delivery and trabeculotomy
- Device
- Lead sponsor
- Sight Sciences, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 15
- States / cities
- Dothan, Alabama • Lake Havasu City, Arizona • Fayetteville, Arkansas + 12 more
- Conditions
- Cataract
- Interventions
- Remote Digital Slit Lamp
- Device
- Lead sponsor
- Eyoto Group Ltd
- Industry
- Eligibility
- 21 Years to 99 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Cataract
- Interventions
- enVista Aspire EA or Aspire Toric ETA IOLs
- Device
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Bullhead City, Arizona • Chandler, Arizona + 54 more
- Conditions
- Cataracts
- Interventions
- Moxifloxacin, besifloxacin
- Drug
- Lead sponsor
- Frank A. Bucci, Jr., M.D.
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Wilkes-Barre, Pennsylvania
- Conditions
- Cataracts
- Interventions
- Tecnis 1-piece Aspheric Acrylic (ZCB00) IOL, AcrySof Natural IQ (SN60WF) IOL
- Device
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Cataract Surgery, Cognitive Impairment
- Interventions
- Remimazolam, Midazolam
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cataract
- Interventions
- Bimatoprost 0.03%
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana
- Conditions
- Normal Cornea, Post Laser Refractive Surgery, Cornea Pathology, Cataract Surgery
- Interventions
- Not listed
- Lead sponsor
- Optovue
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- San Diego, California • Latham, New York
- Conditions
- Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency, Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan and Epilepsy), Alpha-Dystroglycanopathy (Dystroglycanopathy, Congenital With or Without Mental Retardation (Formerly MDC1C)), Alpha-Dystroglycanopathy (Fukuyama CMD), Alpha-Dystroglycanopathy (LGMDR09 FKRP Related (Formerly LGMD2I)), Alpha-Dystroglycanopathy (LGMDR11 POMT1 Related (Formerly LGMD2K)), Alpha-Dystroglycanopathy (LGMDR13 FKTN Related (Formerly LGMD2M)), Alpha-Dystroglycanopathy (LGMDR14 POMT2 Related (Formerly LGMD2N)), Alpha-Dystroglycanopathy (LGMDR15 POMGnT1 Related (Formerly LGMD2O)), Alpha-Dystroglycanopathy (LGMDR19 GMPPB Related (Formerly LGMD2T)), Alpha-Dystroglycanopathy (LGMDR20 ISPD Related (Formerly LGMD2U)), Alpha-Dystroglycanopathy (LGMDR24 POMGnT2 Related), Alpha-Dystroglycanopathy (Muscle Eye Brain Disease (MEB)), Alpha-Dystroglycanopathy (Walker Warburg Syndrome (WWS)), Choline Kinase B Receptor - CHKB, Collagen VI Related Disorders, Collagen XII Related Disorders, Congenital Muscular Dystrophy Not Otherwise Specified (Including Merosin Positive), Congenital Muscular Dystrophy With Cataracts and Intellectual Disability (MDCCAID), Congenital Muscular Dystrophy With Joint Hyperlaxity, Congenital Muscular Dystrophy With Rigid Spine Related to ACTA1, Emery-Dreifuss Muscular Dystrophy, GOLGA2-related Congenital Muscle Dystrophy With Brain Involvement, LMNA Related Disorders, Merosin Deficient CMD (Full or Partial), Nesprin Related MD (SYNE1), SELENON Related Disorders (Previously Known as SEPN1), SELENON Related Myopathy (Aka SEPN1), Telethonin CMD, Congenital Myasthenic Syndrome, Limb-Girdle Muscular Dystrophy, LGMDD01 - DNAJB6 (Formerly LGMD1D), LGMDD05 - Collagen VI Related Bethlem Myopathy (Dominant), LGMDR07 - Telethonin (TCAP) Related (Formerly LGMD2G), LGMDR08 - TRIM Related (Formerly LGMD2H), LGMDR09 - FKRP Related (Formerly LGMD2I), LGMDR10 - Titin (TTN) Related (Formerly LGMD2J), LGMDR11 - POMT1 Related (Formerly LGMD2K), LGMDR13 - Fukutin (FKTN) Related (Formerly LGMD2M), LGMDR14 - POMT2 Related (Formerly LGMD2N), LGMDR15 - POMGnT1 Related (Formerly LGMD2O), LGMDR16 - DAG1 Related Dystroglycanopathy (Formerly LGMD2P), LGMDR17 - Plectin (PLEC) Related (Formerly LGMD2Q), LGMDR18 - TRAPPC11 Related (Formerly LGMD2S), LGMDR19 - GMPPB Related (Formerly LGMD2T), LGMDR20 - ISPD Related (Formerly LGMD2U), LGMDR22 - Collagen VI Related Bethlem Myopathy (Recessive), LGMDR23 - LAMA2 Related, LGMDR24 - POMGnT2 Related
- Interventions
- Not listed
- Lead sponsor
- Cure CMD
- Other
- Eligibility
- Not listed
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2029
- U.S. locations
- 1
- States / cities
- Lakewood, California
- Conditions
- Cataract
- Interventions
- Clareon monofocal Intraocular lens (toric and non-toric models)
- Device
- Lead sponsor
- Eye Consultants of Atlanta
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 34 participants
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Blindness, Cataract, Diabetes Mellitus, Diabetic Retinopathy, Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cataracts
- Interventions
- Intervention
- Device
- Lead sponsor
- Johnson & Johnson Surgical Vision, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Bakersfield, California • Venice, Florida • Mt. Pleasant, South Carolina + 1 more
- Conditions
- Dry Eye
- Interventions
- Lifitegrast 5% Ophthalmic Solution
- Drug
- Lead sponsor
- Bucci Laser Vision Institute
- Other
- Eligibility
- 60 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Wilkes-Barre, Pennsylvania
- Conditions
- Cataract
- Interventions
- PureSee IOL
- Device
- Lead sponsor
- Vance Thompson Vision
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Cataract
- Interventions
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Vehicle 0.3%
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Cataracts
- Interventions
- Bromfenac, Moxifloxacin hydrochloride, Prednisolone Acetate
- Drug
- Lead sponsor
- Bp Consulting, Inc
- Network
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Los Altos, California
- Conditions
- Aphakia
- Interventions
- AcrySof single-piece IOL, AcrySof multi-piece IOL
- Device
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- Not listed
- Enrollment
- 138 participants
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Burbank, California • Jacksonville, Florida • Rock Island, Illinois + 3 more
- Conditions
- Intracameral Antibiotics, Cataract Surgery, Phacoemulsification, Endophthalmitis, Vancomycin, Moxifloxacin
- Interventions
- Vancomycin, Moxifloxacin, Placebo
- Drug
- Lead sponsor
- Panhandle Eye Group, LLP
- Other
- Eligibility
- 30 Years to 100 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Amarillo, Texas
- Conditions
- Nuclear Cataract
- Interventions
- High Intraocular Pressure (IOP), Low Intraocular Pressure (IOP)
- Other
- Lead sponsor
- Matthew Rauen
- Other
- Eligibility
- Not listed
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- West Des Moines, Iowa
- Conditions
- Cataract
- Interventions
- Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}, Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}
- Drug
- Lead sponsor
- Inder Paul Singh, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Venice, Florida • Racine, Wisconsin